165 related articles for article (PubMed ID: 33030818)
1. Tumor and germline next generation sequencing in high grade serous cancer: experience from a large population-based testing program.
Care M; McCuaig J; Clarke B; Grenier S; Kim RH; Rouzbahman M; Stickle N; Bernardini M; Stockley TL
Mol Oncol; 2021 Jan; 15(1):80-90. PubMed ID: 33030818
[TBL] [Abstract][Full Text] [Related]
2. The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high-grade serous ovarian cancer: a national retrospective audit.
Frugtniet B; Morgan S; Murray A; Palmer-Smith S; White R; Jones R; Hanna L; Fuller C; Hudson E; Mullard A; Quinton AE
BJOG; 2022 Feb; 129(3):433-442. PubMed ID: 34657373
[TBL] [Abstract][Full Text] [Related]
3. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
4. Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
Hussein YR; Ducie JA; Arnold AG; Kauff ND; Vargas-Alvarez HA; Sala E; Levine DA; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):404-9. PubMed ID: 26574845
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
[TBL] [Abstract][Full Text] [Related]
6. Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract][Full Text] [Related]
7. Predicting the likelihood of a
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA repair: the genome as a potential biomarker.
Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
[TBL] [Abstract][Full Text] [Related]
9. Examining the Diagnostic Yield of Tumour Testing and Qualifying Germline Concordance for Hereditary Cancer Variants in Patients with High-Grade Serous Carcinoma.
Goebel EA; Kerkhof J; Dzyubak O; McLachlin CM; McGee J; Sadikovic B
Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011309
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
[TBL] [Abstract][Full Text] [Related]
11. [Detecting Large Germline Rearrangements of BRCA1 by Next Generation Tumor Sequencing].
Minucci A; Mazzuccato G; Marchetti C; Pietragalla A; Scambia G; Fagotti A; Urbani A
Mol Biol (Mosk); 2020; 54(4):688-698. PubMed ID: 32840490
[TBL] [Abstract][Full Text] [Related]
12. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
13. Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.
McDaniel AS; Stall JN; Hovelson DH; Cani AK; Liu CJ; Tomlins SA; Cho KR
JAMA Oncol; 2015 Nov; 1(8):1128-32. PubMed ID: 26181193
[TBL] [Abstract][Full Text] [Related]
14. Validation of BRCA testing on cytologic samples of high-grade serous carcinoma.
Lou SK; Grenier S; Care M; McCuaig J; Stockley TL; Clarke B; Ruff HM; Boerner SL
Cancer Cytopathol; 2021 Nov; 129(11):907-913. PubMed ID: 34157791
[TBL] [Abstract][Full Text] [Related]
15. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
16. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
17. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
[TBL] [Abstract][Full Text] [Related]
18. Detection of somatic BRCA1/2 mutations in ovarian cancer - next-generation sequencing analysis of 100 cases.
Koczkowska M; Zuk M; Gorczynski A; Ratajska M; Lewandowska M; Biernat W; Limon J; Wasag B
Cancer Med; 2016 Jul; 5(7):1640-6. PubMed ID: 27167707
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
20. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
